Rare Disease · In-Market · Updated August 2026
Late-onset Pompe is routinely mistaken for limb-girdle muscular dystrophy. The patients are already in the system; they are under the wrong diagnosis.
Most Pompe patients have the late-onset form, and its presentation overlaps closely enough with limb-girdle muscular dystrophy that a substantial share sit misdiagnosed in neuromuscular clinics. The funnel therefore has to be built by phenotype rather than from headline prevalence, and case-finding in the misdiagnosed population is a larger source of volume than switching patients already on therapy.
Positioning a next-generation enzyme replacement therapy is a segment argument, not an average-patient argument. No challenger has cleanly beaten the long-established incumbent on its primary endpoint, and a value story that implies otherwise will not survive scrutiny. What differentiates is performance in a defined subgroup, and the case has to be built there and confined there.
Infusion burden and anti-drug antibodies belong in the value case as lifetime variables rather than per-cycle costs. Every approved therapy is a lifelong intravenous infusion, so the economics compound across decades: infusion-chair time, travel, immunogenicity management and the drug cost itself. Framed annually, next-generation agents look like a marginal upgrade at a premium; framed across a treatment lifetime, the argument changes.
AXLRx Pompe reports reconcile registry-confirmed counts against true prevalence across the US, UK and Gulf, size the switchable late-onset pool by phenotype, and build a lifetime-infusion value case rather than an annual one. Each report is a sample output of the AXLRx commercial consulting engine, and the same analysis can be commissioned for your asset and market.
For the wider context, see orphan drug approvals in numbers: FDA and EMA orphan approvals counted by year, condition and sponsor.
Pompe disease is a metabolic myopathy caused by acid alpha-glucosidase (GAA) deficiency. An estimated 5,000 to 10,000 people are affected in the US, of whom late-onset Pompe disease (LOPD) makes up 70 to 80 percent and infantile-onset disease (IOPD) the remainder. LOPD retains residual GAA activity above 1 percent and presents as proximal muscle weakness with progressive respiratory decline; IOPD shows near-absent GAA and hypertrophic cardiomyopathy within the first months of life. GCC consanguinity lifts incidence to 1:20,000 to 30,000 against roughly 1:40,000 globally.
Confirmation rests on a dried-blood-spot GAA enzyme assay, but the path there is slow. Late-onset patients are typically diagnosed years late, often after a limb-girdle muscular dystrophy workup, and in the GCC frequently not until forced vital capacity has fallen to 55 to 65 percent predicted. Newborn screening is reshaping the top of the funnel, Saudi Arabia added the GAA dried-blood-spot assay to its national panel in 2021 and expects 25 to 35 infantile-onset detections a year. The result is a wide gap between true prevalence and identified patients.
Three enzyme replacement therapies (ERTs) are FDA-approved. The incumbent, alglucosidase alfa (Lumizyme/Myozyme, Sanofi), dates to 2006 and 2010. Two next-generation agents now compete: avalglucosidase alfa (Nexviazyme, Sanofi, 2021), engineered for enhanced mannose-6-phosphate uptake, and cipaglucosidase alfa plus miglustat (Pombiliti plus Opfolda, Amicus Therapeutics, 2023), pairing an enzyme with an oral stabilising chaperone. All three are intravenous infusions, and the Amicus regimen adds co-administered oral Opfolda. In the COMET head-to-head, avalglucosidase was non-inferior to alglucosidase on forced vital capacity with a numerically greater 6-minute-walk gain.
The two phenotypes are found through separate mechanisms and must be sized separately. For infantile-onset disease we model the newborn-screening funnel, panel adoption by state or country, birth cohort, and confirmed detection rate, the pathway that led Saudi Arabia to project 25 to 35 detections a year after its 2021 GAA screening expansion. For late-onset disease we model a diagnosis funnel by phenotype: symptomatic prevalence, the share still mislabelled as limb-girdle muscular dystrophy, and conversion once a dried-blood-spot GAA assay is ordered. Each funnel yields a different identified count and a different growth curve, so a single prevalence number would misstate both the near-term addressable pool and its trajectory.
We build the funnel by phenotype rather than from headline prevalence. Starting from 5,000 to 10,000 US patients, roughly 70 to 80 percent are late-onset, of whom about 2,000 are on enzyme replacement therapy. Within that treated pool we size the inadequate-responder segment, an estimated 375 to 600 patients, or 25 to 30 percent, driven largely by the anti-drug antibodies that develop in 30 to 40 percent of treated patients. That switch-eligible cohort, not the prevalence figure, is the addressable market. Switch modelling then layers payer step-edits, which require documented inadequate response before a next-generation ERT is authorised, onto physician and centre-level switching intent.
Both are modelled as lifetime variables, not per-cycle costs. Every approved ERT is an intravenous infusion carrying roughly $400,000 a year in drug cost alone, so we build a lifetime-infusion value case that captures chair time, home-versus-hospital administration, and capacity constraints such as the 6 to 8 infusion centres serving the GCC. Anti-drug antibodies enter twice: as a clinical driver of the inadequate-responder segment, and as the sharpest switch rationale, since high-titre antibodies blunt response to first-generation enzyme. The value story therefore rests on immunogenicity-adjusted durability and administration burden, the levers a next-generation agent can move, rather than on a headline efficacy delta.
We position on the segment, not the average patient. Neither next-generation agent decisively beat alglucosidase on its primary endpoint, avalglucosidase reached non-inferiority with a numerically larger 6-minute-walk gain in COMET, while cipaglucosidase plus miglustat missed statistical superiority in PROPEL. Because no clean efficacy win exists, positioning turns on the antibody-positive inadequate responder and on switching economics rather than a first-line displacement claim. We test two strategic options against the evidence: an incremental-improvement claim across all treated patients, or a standalone submission built around the inadequate-responder subgroup, and we size each against the switch-eligible pool the funnel produces.
These questions sit on one thesis: in Pompe disease, the identification funnel is the strategy. AXLRx builds that funnel across the US, UK and GCC, reconciling registry-confirmed counts against true prevalence, separating the newborn-screening and late-onset diagnosis pathways, and sizing the inadequate-responder pool a new ERT can actually convert. Disease-landscape, market-sizing and patient-flow, competitive-intelligence, payer-and-pricing, and KOL-mapping work then turn that funnel into an access-gated commercial target. The output is not an epidemiology slide but an addressable, switch-eligible number a launch team can plan against.